Table 1

Summary of clinicopathological parameters and immunohistochemical staining patterns of 54 ovarian tumorsa

Clinicopathological parameterNo. (%)Positive Expression by IHC no. (%)
MatriptaseHAI-1
FIGO stage
 I31 (57%)25 (81%)10 (32%)
 II3 (6%)3 (100%)0 (0%)
 III19 (35%)11 (58%)1 (5%)
 IV1 (2%)0 (0%)0 (0%)
Histological grade
 Well differentiated (grade I)11 (20%)10 (91%)5 (45%)
 Moderate (grade II)16 (30%)11 (69%)2 (12%)
 Poor (grade III)22 (41%)14 (64%)3 (14%)
 Unknown5 (9%)4 (80%)1 (20%)
Patient status
 Death from ovarian cancer30 (55%)20 (67%)5 (17%)
 Death other than ovarian cancer2 (6%)1 (50%)1 (50%)
 Alive at time of study22 (39%)18 (82%)5 (23%)
Residual tumor after surgery
 <2 cm46 (85%)31 (67%)11 (24%)
 2–5 cm4 (7.5%)4 (100%)0 (0%)
 >5 cm4 (7.5%)4 (100%)0 (0%)
Tumor histology
 Serous18 (33%)11 (61%)1 (5%)
 Mucinous8 (15%)6 (75%)3 (33%)
 Endometrioid17 (31%)14 (82%)6 (35%)
 Clear cell9 (17%)6 (67%)0 (0%)
 Mixed endometrioid/clear cell1 (2%)1 (100%)0 (0%)
 Unclassified carcinoma1 (2%)1 (100%)1 (100%)
  • a Patient and tumor clinicopathological summary profile. A summary of the clinical and pathological data relating to the panel of ovarian tumors used in this study and the scorings obtained from the immunohistochemical analysis of matriptase (S5 monoclonal antibody) and HAI-1 (M58 monoclonal antibody) expression is shown.